Brokerages expect Vericel Corporation (NASDAQ:VCEL) to report ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vericel’s earnings. Vericel reported earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The company is expected to report its next quarterly earnings report on Friday, March 9th.

On average, analysts expect that Vericel will report full year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.64) to ($0.56). For the next year, analysts expect that the business will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.48) to ($0.24). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Vericel.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%. The firm had revenue of $14.26 million for the quarter.

A number of equities research analysts have issued reports on the stock. ValuEngine lowered shares of Vericel from a “hold” rating to a “sell” rating in a research note on Friday. BTIG Research set a $6.00 target price on shares of Vericel and gave the company a “buy” rating in a research note on Monday, October 2nd. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $7.00 target price on shares of Vericel in a research note on Thursday, August 10th.

Vericel (NASDAQ:VCEL) traded up $0.05 during midday trading on Friday, reaching $4.50. 633,705 shares of the company’s stock traded hands, compared to its average volume of 484,714. Vericel has a 12-month low of $2.25 and a 12-month high of $6.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50.

Several large investors have recently modified their holdings of VCEL. Bank of New York Mellon Corp boosted its stake in shares of Vericel by 13.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 4,523 shares during the period. First Washington CORP acquired a new stake in shares of Vericel during the 2nd quarter valued at $2,230,000. Vanguard Group Inc. boosted its stake in shares of Vericel by 7.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock valued at $4,002,000 after buying an additional 88,645 shares during the period. Archon Capital Management LLC acquired a new stake in shares of Vericel during the 2nd quarter valued at $4,412,000. Finally, Perkins Capital Management Inc. boosted its stake in shares of Vericel by 118.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock valued at $3,376,000 after buying an additional 305,000 shares during the period. 33.17% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “-$0.10 Earnings Per Share Expected for Vericel Corporation (VCEL) This Quarter” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/02/0-10-earnings-per-share-expected-for-vericel-corporation-vcel-this-quarter.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.